PT-141 vs. 'the blue pill': separating peptide hype from evidence

What did @drveliranyssen actually say?

The audio in this video is heavily distorted and largely unintelligible in its transcribed form, which creates an immediate verification problem. Based on the caption and the fragmented transcript, the core claims appear to be: PT-141 (bremelanotide) works through a different mechanism than PDE5 inhibitors like sildenafil, it acts on the central nervous system rather than directly on blood flow, it has an approved use in women with hypoactive sexual desire disorder, and it is available as a research peptide through the sponsor Ultimate Biolabs. The framing, "Besser als die blaue Pille" (better than the blue pill), sets up a direct superiority comparison. That framing is the most problematic part of this video, and we will get into why below.

Does the science back this up?

The mechanistic claim is the strongest part of this video. PT-141 is a melanocortin receptor agonist, specifically MC3R and MC4R, and it does act centrally rather than through peripheral vasodilation. That much is documented. A 2008 study by Diamond et al. in the Journal of Sexual Medicine confirmed bremelanotide's central mechanism in men with erectile dysfunction. The FDA approved bremelanotide (Vyleesi) in 2019 specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Palatin Technologies' clinical data showed statistically significant improvement in desire scores versus placebo. However, "better than the blue pill" as a blanket claim is not supported by head-to-head trial data. There are no large randomized controlled trials directly comparing PT-141 to sildenafil or tadalafil in the same population. Saying one mechanism is superior to another is an opinion dressed up as a fact.

What did they get wrong (or right)?

Credit where it is due: the central nervous system mechanism claim appears to be accurate. PT-141 does not work like sildenafil. Sildenafil inhibits PDE5 to increase cGMP and relax smooth muscle in penile tissue. PT-141 activates melanocortin receptors in the hypothalamus to modulate sexual motivation. These are genuinely different pathways, and that distinction matters clinically.

What is wrong, or at least misleading:

• The "better than" framing implies a proven superiority that does not exist in the peer-reviewed literature.
• The FDA approval for bremelanotide is specifically for women with HSDD, not as a general libido booster or erectile dysfunction treatment for men. Presenting it as a general-purpose alternative to Viagra overstates the approved indication.
• Linking to a "research peptide" supplier in the same video where clinical benefits are discussed is a regulatory grey area. Research peptides are not pharmaceutical-grade, they are not FDA-approved for human use in that form, and the audience watching a TikTok video is almost certainly not a licensed researcher.
• The transcript is too garbled to assess whether dosing or stacking advice was given, but the caption's promotional code structure suggests commercial intent that should be disclosed more explicitly.

What should you actually know?

PT-141 has a real pharmacological profile and a legitimate FDA approval history. It is not snake oil. But the gap between "this mechanism is interesting" and "this is better than Viagra" is where the evidence runs out.

A few things worth knowing before anyone considers this compound:

• Bremelanotide was studied for male erectile dysfunction in early trials but was not pursued for that indication partly due to a transient blood pressure-raising effect, specifically an increase in mean arterial pressure, which is the opposite of what sildenafil does. That side effect profile matters (Shadiack et al., 2007, Annals of the New York Academy of Sciences).
• The FDA-approved version (Vyleesi) is an autoinjector for subcutaneous use. Research peptides sold online are not equivalent to this. Purity, sterility, and dosing accuracy are not guaranteed.
• Anyone with cardiovascular risk factors should not be comparing PT-141 to sildenafil without a physician's input. The mechanisms differ, and so do the contraindication profiles.

The video's promotional structure, a creator with an affiliate code selling research peptides while discussing clinical benefits, is exactly the setup that regulatory agencies like the FDA and FTC have flagged in enforcement actions against similar accounts. That does not make the science wrong, but it does mean viewers should separate the pharmacology from the pitch.